Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADH1A | P07327 | 2/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11113407 | 0.79 | ADH1A (0.41) | ADH1AADH1CNPSR1TSHRALDH1A1 | |
| SCHEMBL11115307 | 0.75 | CES2 (0.38) | ADH1AADH1CTSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL504178 | 0.73 | ADH1A (0.37) | ADRA2APDE4AADRA1AADH1AADH1C | |
| SCHEMBL56768 | 0.72 | TSHR (0.36) | TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL103333 | 0.72 | ADRA2A (0.40) | ADRA2APDE4AADRA1AALDH1A1 | |
| Ethyl Nitrosourea SCHEMBL27699579 | 0.71 | ADRA2A (0.41) | ADRA2APDE4AADRA1AADH1AADH1C | |
| SCHEMBL7207383 | 0.71 | ALDH1A1 (0.33) | ADRA2APDE4AADRA1AADH1AADH1C | |
| SCHEMBL846156 | 0.69 | ADRA2A (0.53) | ADRA2APDE4AADRA1ANPSR1TSHR | |
| SCHEMBL7306685 | 0.68 | KDM4E (0.38) | ADH1AADH1CNPSR1TSHRALDH1A1 | |
| SCHEMBL11174425 | 0.67 | MEN1 (0.40) | ADH1AADH1CNPSR1TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130046171-A1 | DEVICE AND METHOD FOR ACCESSING AND TREATING DUCTS OF MAMMARY GLANDS | ATOSSA THERAPEUTICS, INC. | 2013-02-21 | — | — | US | claimed |
| US-8277807-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2012-10-02 | — | — | US | claimed |
| US-20110091452-A1 | 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies | BIOTICA TECHNOLOGY LIMITED (GB) | 2011-04-21 | — | — | US | claimed |
| US-20100069781-A1 | DEVICE AND METHOD FOR ACCESSING AND TREATING DUCTS OF MAMMARY GLANDS | ATOSSA THERAPEUTICS, INC. | 2010-03-18 | — | — | US | claimed |
| US-20100068203-A1 | 17-Oxymacbecin Derivatives and Their Use in the Treatment of Cancer and/or B-Cell Malignancies | BIOTICA TECHNOLOGY LIMITED (GB) | 2010-03-18 | — | — | US | claimed |
| US-20090298804-A1 | Novel Compounds and Methods for Their Production | BIOTICA TECHNOLOGY LIMITED (GB) | 2009-12-03 | — | — | US | claimed |
| WO-2009129352-A2 | DEVICE AND METHOD FOR ACCESSING AND TREATING DUCTS OF MAMMARY GLANDS | WINDY HILL MEDICAL (US) | 2009-10-22 | — | — | WO | claimed |
| US-20090253667-A1 | 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer | BIOTICA TECHNOLOGY LIMITED (GB) | 2009-10-08 | — | — | US | claimed |
| US-20090209507-A1 | 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies | BIOTICA TECHNOLOGY LIMITED (GB) | 2009-08-20 | — | — | US | claimed |
| US-20090209494-A1 | 21-DEOXYMACBECIN ANALOGUES USEFUL AS ANTITUMOR AGENTS | MARTIN CHRISTINE JANET | 2009-08-20 | — | — | US | claimed |
| WO-2007128827-A1 | 17-OXYMACBECIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND/OR B-CELL MALIGNANCIES | BIOTICA TECHNOLOGY LIMITED (GB) | 2007-11-15 | — | — | WO | claimed |
| WO-2007128829-A2 | 18,21-DIDESOXYMACBECIN DERIVATIVES FOR THE TREATMENT OF CANCER | BIOTICA TECHNOLOGY LIMITED (GB) | 2007-11-15 | — | — | WO | claimed |
| WO-2007113270-A1 | 15-O-DESMETHYLMACBECIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER OR B-CELL MALIGNANCIES | BIOTICA TECHNOLOGY LTD. (GB) | 2007-10-11 | — | — | WO | claimed |
| WO-2007113268-A1 | 4, 5-DIHYDROMACBECIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER OR B-CELL MALIGNANCIES. | BIOTICA TECHNOLOGY LTD. (GB) | 2007-10-11 | — | — | WO | claimed |
| WO-2007113269-A2 | 15-DESMETHOXYMACBECIN DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | BIOTICA TECHNOLOGY LTD. (GB) | 2007-10-11 | — | — | WO | claimed |
| WO-2007113266-A2 | NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BIOTICA TECHNOLOGY LTD. (GB) | 2007-10-11 | — | — | WO | claimed |
| WO-2007074347-A1 | 21-DEOXYMACBECIN ANALOGUES USEFUL AS ANTITUMOR AGENTS | BIOTICA TECHNOLOGY LTD. (GB) | 2007-07-05 | — | — | WO | claimed |
| US-6932777-B2 | Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 2005-08-23 | — | — | US | claimed |
| US-6656918-B2 | Contacting the ductal epithelium of the exocrine gland with epithelium destroying agents such as ethanol and vaccinia virus | JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2003-12-02 | — | — | US | claimed |
| EP-0909184-B1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | UPJOHN CO (US) | 2003-09-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091452-A1 | 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies | BCL6, CD22, BCL6B | ADRA2A 2429/4885PDE4A 2518/4885ADRA1A 2220/4885 |
| US-20090209494-A1 | 21-DEOXYMACBECIN ANALOGUES USEFUL AS ANTITUMOR AGENTS | BCL3, CDC42, BECN1 | ADRA2A 3380/4885PDE4A 1362/4885ADRA1A 2595/4885 |
| US-20100068203-A1 | 17-Oxymacbecin Derivatives and Their Use in the Treatment of Cancer and/or B-Cell Malignancies | BCL3, BCL6, BCL6B | ADRA2A 3214/4885PDE4A 2472/4885ADRA1A 2381/4885 |
| US-20090209507-A1 | 15-O-Desmethylmacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies | C1QBP, CD22, BCL3 | ADRA2A 3775/4885PDE4A 4417/4885ADRA1A 3444/4885 |
| US-20090298804-A1 | Novel Compounds and Methods for Their Production | BCL3, BCL6, CD22 | ADRA2A 4166/4885PDE4A 1210/4885ADRA1A 3983/4885 |
| US-20090253667-A1 | 18 ,21-Didesoxymacbecin Derivatives for the Treatment of Cancer | BCL3, BECN1, CD22 | ADRA2A 3328/4885PDE4A 1071/4885ADRA1A 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.